Are you Xiaohui Wang?

Claim your profile

Publications (2)2.53 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Mesenchymal stem cells (MSCs) or MSC-like cells have now been isolated from various sites, including different types of tumor tissues. Whether MSCs or MSC-like cells in different tumor tissues possess differentiated biological characteristics remains unclear, and the correlation between MSCs or MSC-like cells and tumors has been a controversial topic. In the present study, we isolated MSC-like cells from human esophageal carcinoma (hEC-MSCs) and adjacent non-cancerous tissues (hECN-MSCs). Although the two types of MSC-like cells were in different microenvironments and had certain differences, they possessed similar morphological properties and surface antigens, including CD13, CD29, CD44 and CD105. Our results indicated that hEC-MSCs and hECN-MSCs are similar in a number of ways. This may have implications for further research on the esophageal carcinoma microenvironment and its pathological mechanism.
    Oncology letters 01/2013; 5(1):179-184. · 0.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human embryonic stem cells (hESCs) are usually maintained in an undifferentiated state by co-culture with feeder cells. The feeder cells are important for the growth of hESCs. A novel spontaneously immortalizated mouse fetal liver stromal cell line, named KM3, was isolated from a 13.5‑day mouse fetal liver. In this study, we examined whether KM3 cells could be used as feeders to support the growth of hESCs. hESCs cultured on KM3 cells showed a similar proliferation rate and characteristics to mouse embryonic fibroblasts (MEFs) after prolonged culture, including morphology, unlimited and undifferentiated proliferative ability, maintenance of normal karyotypes, formation of embryoid bodies in vitro and typically immature teratomas in vivo. Our results indicate that the immortalized KM3 cell line has the potential to support the growth and maintenance of hESCs. The cell line may be used for the large-scale expansion of hESCs in a low-cost and less labor-intensive manner.
    Oncology Reports 07/2012; 28(4):1385-91. · 2.30 Impact Factor